Skip to main content
Fig. 4 | Diagnostic Pathology

Fig. 4

From: Estrogen receptor-negative/progesterone receptor-positive breast cancer has distinct characteristics and pathologic complete response rate after neoadjuvant chemotherapy

Fig. 4

Relationship of different HR combination subgroups and BCSS in the whole series (Kaplan–Meier method and log-rank test) Legend: The four different HR combinations were significantly different from the BCSS of the patients (log-rank, P < 0.001). The prognosis of the patients with the ER-/PR + phenotype was similar to that of the patients with the ER-/PR- phenotype (P = 0.995), the best prognosis of the patients with the ER + /PR + phenotype, and the prognosis of the patients with the ER + /PR- phenotype was situated between the ER + /PR + phenotype (best outcome) and ER-/PR + phenotype (worst outcome) (P < 0.001). Patients with ER-/PR- phenotype had a higher risk of death than the other groups, with a mean survival time of 106.17 months. Abbreviation: ER, estrogen receptor; PR, progesterone receptor

Back to article page

Diagnostic Pathology

ISSN: 1746-1596

Contact us